• Publications
  • Influence
Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma
Despite recent advances, median survival for patients with resectable glioblastoma multiforme (GBM) is only 12 to 15 months. We previously observed minimal toxicity and a 9.0-month median survivalExpand
  • 73
  • 4